1. Home
  2. IBRX vs KNX Comparison

IBRX vs KNX Comparison

Compare IBRX & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$7.59

Market Cap

8.4B

Sector

Health Care

ML Signal

HOLD

Logo Knight-Swift Transportation Holdings Inc.

KNX

Knight-Swift Transportation Holdings Inc.

HOLD

Current Price

$57.59

Market Cap

7.0B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBRX
KNX
Founded
2014
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trucking Freight/Courier Services
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
8.4B
7.0B
IPO Year
2015
2010

Fundamental Metrics

Financial Performance
Metric
IBRX
KNX
Price
$7.59
$57.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
18
Target Price
$12.57
$61.39
AVG Volume (30 Days)
24.1M
2.7M
Earning Date
05-11-2026
04-22-2026
Dividend Yield
N/A
1.30%
EPS Growth
38.71
N/A
EPS
N/A
0.41
Revenue
$113,288,000.00
$7,469,689,000.00
Revenue This Year
$88.59
$5.92
Revenue Next Year
$131.15
$7.91
P/E Ratio
N/A
$135.17
Revenue Growth
668.31
0.80
52 Week Low
$1.83
$36.69
52 Week High
$12.43
$64.10

Technical Indicators

Market Signals
Indicator
IBRX
KNX
Relative Strength Index (RSI) 48.47 54.65
Support Level $2.25 $51.70
Resistance Level $8.28 $59.89
Average True Range (ATR) 0.93 2.00
MACD -0.24 0.37
Stochastic Oscillator 39.00 95.69

Price Performance

Historical Comparison
IBRX
KNX

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

About KNX Knight-Swift Transportation Holdings Inc.

Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.

Share on Social Networks: